XNYS · Medical Instruments & Supplies
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$180.94-0.24%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
47/100
Moderate
Score components
TickerWhale View
Becton Dickinson & Company scores 47 out of 100 overall, which we rate moderate. Technical is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
- Risk
Quality & growth
30%27Weak
- Revenue growth 5.2%
- EPS growth -39.5%
Valuation
25%45Weak
- P/E 52.9
- EV/Sales 3.2
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
#250 by market cap in our coverage · ~72,000 employees · Listed 1963-09-25 · www.bd.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#105 / 139sector rank by TickerWhale Score
TickerWhale Score 47 vs sector average 55.1 (-8.1)
Revenue growth (industry)Top 79%
Gross margin (industry)Top 67%
Return on equity (industry)Top 53%
P/E (industry)Pricier than 75%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
80/100Strong vs universe
Ranks 80th of 100 covered names on our technical composite — the composite itself scores 64/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 3 sell · 3 neutral of 8 votes
TickerWhale rates BDX's technical setup strong — 80th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
5 / 9constructive
- vs 200-day+5.7%
- vs 50-day+3.5%
Momentum
Mixed
- RSI (14)50 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength24· trending
- MACD (12,26,9)sell(histogram -1.215)
How the classic verdict is reached
Moving averages (9) agree on buy — 5 buy vs 2 sell — and carry one vote between them.
Oscillators (7) vote individually: 1 buy · 3 sell · 3 neutral.
Result — 2 buy vs 3 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)52.9
- P/S (TTM)2.4
- P/B2.0
- EV/EBITDA—
- EV/Sales3.2
- PEG—
Profitability & returns
- Gross margin46.4%
- Net margin4.5%
- ROE3.9%
- Debt/Equity0.69
Growth
- Revenue growth (YoY)5.2%
- EPS growth (YoY)-39.5%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $49.8B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Sep '25 | Sep '24 | Sep '23 |
|---|---|---|---|
| Revenue | $21.8B | $20.2B | $19.4B |
| Gross profit | $9.9B | $9.1B | $8.2B |
| Operating income | $2.6B | $2.4B | $2.1B |
| Net income | $1.7B | $1.7B | $1.5B |
| EPS (diluted) | $5.82 | $5.86 | $4.94 |
| Free cash flow | $2.7B | $3.1B | $2.1B |
| Cash | $777M | $1.9B | $1.5B |
| Total debt | $19.2B | $20.1B | $15.9B |
| Equity | $25.4B | $25.9B | $25.8B |
| Net debt | $18.4B | $18.3B | $14.4B |
| Debt / equity | 0.76 | 0.78 | 0.62 |
| Liabilities / assets | 0.54 | 0.55 | 0.51 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BDXCurrentBecton Dickinson & Company | 47 | 64 | 52.9 | — | 2.0 | 3.2 | $180.94 | -0.24% | +5.2% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.